Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Ginkgo Bioworks Holdings Inc DNA

Alternate Symbol(s): DNABW

Chemicals Specialty Chemicals

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration... see more

Add To Watchlist

Recent & Breaking News (NYSE:DNA)

Ginkgo Bioworks Announces Participation in Goldman Sachs 44th Annual Global Healthcare Conference

PR Newswire June 5, 2023

Ginkgo Bioworks and Centrient Pharmaceuticals Announce Expansion of Partnership Following Success of Initial Project to Bring Sustainable Innovation to the Generic API Space

PR Newswire May 25, 2023

Ginkgo Bioworks Reports First Quarter 2023 Financial Results

PR Newswire May 10, 2023

Octarine Bio and Ginkgo Bioworks Announce Partnership to Produce Natural Colors

PR Newswire May 9, 2023

Ginkgo Bioworks Partners with Boehringer Ingelheim to Develop Breakthrough Therapies for Hard-to-Treat Diseases

PR Newswire May 8, 2023

Ginkgo Bioworks Announces Appointment of Steven P. Coen as Chief Accounting Officer

PR Newswire May 5, 2023

Ginkgo Bioworks Announces Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

PR Newswire May 4, 2023

Ginkgo Bioworks Announces Date of First Quarter 2023 Results Presentation

PR Newswire May 3, 2023

Grabar Law Office Investigates Claims on Behalf of Shareholders of Ginkgo Bioworks Holdings, Inc. (DNA) After Securities Fraud Class Action Survives Motion to Dismiss

Newsfile April 25, 2023

Visolis and Ginkgo Bioworks Announce Partnership to Improve Microbial Strain for Bio-Isoprene and Sustainable Aviation Fuel Production

PR Newswire April 24, 2023

Ginkgo Bioworks Previews Today's Annual Ferment Conference

PR Newswire April 19, 2023

Cambrium and Ginkgo Bioworks Complete Successful Collaboration on Data-Driven Cell Factory Engineering

PR Newswire April 18, 2023

Ginkgo Bioworks and Syngenta Seeds Announce Collaboration to Develop New Traits for the Next Generation of Seed Technology

PR Newswire April 17, 2023

Ginkgo Bioworks and the Government of the Democratic Republic of the Congo Announce Plans to Develop and Implement New Biosecurity Capabilities in the Region

PR Newswire April 14, 2023

Ginkgo Bioworks and WARF Announce Partnership to Discover Next Generation GD2 CAR T-Cell Therapies

PR Newswire April 13, 2023

Ginkgo Bioworks to Host Annual Ferment Conference

PR Newswire April 12, 2023

Sensible Biotechnologies Raises $4.2mn in a Pre-Seed Financing Round to Revolutionize mRNA Manufacturing

PR Newswire April 6, 2023

Grabar Law Office Investigates Claims on Behalf of Shareholders of Ginkgo Bioworks Holdings, Inc. (DNA) f/k/a Soaring Eagle Acquisition Corp. (SRNG) After Securities Fraud Class Action Survives Motion to Dismiss

Newsfile April 5, 2023

Ginkgo Bioworks Strengthens End-to-End R&D Capabilities in Gene Therapy through Acquisition of StrideBio's AAV Capsid Discovery and Engineering Platform Assets

PR Newswire April 5, 2023

Solvay Announces Strategic Collaboration With Ginkgo Bioworks And Expands Its R&I Footprint In The United States

PR Newswire April 4, 2023